Table 1.
Clinical characteristics of patients included in analyses for 1 year post-COVID-19.
| HC (2021) (n = 8) | Completely asymptomatic (n = 7) | Mild (n = 9) | Severe (n = 8) | P a | |
|---|---|---|---|---|---|
| Age, median years (range) | 39 (22–50) | 25 (20–28) | 53 (24–72) | 63 (39–76) | 0.001 |
| Male gender, n (%) | 4 (50.0) | 5 (71.4) | 3 (33.3) | 6 (75.0) | 0.831 |
| Underlying diseases, n (%) | |||||
| Diabetes mellitus | 0 (0) | 0 (0) | 3 (33.3) | 3 (37.5) | 0.108 |
| Hypertension | 0 (0) | 0 (0) | 2 (22.2) | 5 (62.5) | 0.009 |
| Maximal O2 demand | NA | No | No | HFNC (NP to MV) | NA |
| Treatment, n (%) | |||||
| Remdesivir | NA | 0 (0) | 1 (11.1) | 7 (87.5) | <0.001 |
| Baricitinib | NA | 0 (0) | 1 (11.1) | 3 (37.5) | 0.054 |
| Steroid | NA | 0 (0) | 0 (0) | 2 (25.0) | 0.079 |
| Days of sample collection from the onset of COVID-19, median (range) | |||||
| For 8 months | NA | 231 (229–235) | 237 (192–265) | 197 (185–220) | 0.003 |
| For 12 months | NA | 351 (343–355) b | 370 (315–383) | 356 (318–368) | 0.405 |
HC, healthy control; NA, not applicable; HFNC, high flow nasal canula; NP, nasal prong; MV, mechanical ventilation.
a
Healthy control group was not included in the P-value calculation.
b
One patient was unavailable at 12-months post COVID-19.